NEW YORK (360Dx) – Based on an unexpected finding from a study of inflammation, researchers at VIB and Ghent University in Belgium have developed an immunoassay that may improve the diagnosis of familial Mediterranean fever (FMF) and lead to earlier therapy.

The scientists, led by Mohamed Lamkanfi at the Center for Inflammation Research at VIB and Ghent University, are currently validating the assay and are transferring it to other clinical laboratories. In addition, they are in discussion with a potential licensing partner who might commercialize the test as a diagnostic kit.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.